Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease.

Howe R, Mirakian RM, Pillai P, Gane S, Darby YC, Scadding GK.

World Allergy Organ J. 2014 Jul 29;7(1):18. doi: 10.1186/1939-4551-7-18. eCollection 2014.

2.

Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis.

Miller B, Mirakian R, Gane S, Larco J, Sannah AA, Darby Y, Scadding G.

Clin Exp Allergy. 2013 Aug;43(8):874-80. doi: 10.1111/cea.12110.

3.

An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma.

Ragab S, Parikh A, Darby YC, Scadding GK.

Clin Exp Allergy. 2001 Sep;31(9):1385-91.

PMID:
11591188
4.

Two patterns of changes in nasal nitric oxide after lysine aspirin nasal challenge in patients with aspirin-exacerbated respiratory disease.

Tworek D, Kuprys-Lipinska I, Pietruszewska W, Kuna P.

Am J Rhinol Allergy. 2012 Nov-Dec;26(6):428-32. doi: 10.2500/ajra.2012.26.3818. Epub 2012 Oct 9.

PMID:
23050514
5.

The nose as a target organ in the diagnosis of severe aspirin-exacerbated respiratory disease.

González-Pérez R, Poza-Guedes P, Vives-Conesa R.

Am J Rhinol Allergy. 2011 May-Jun;25(3):166-9. doi: 10.2500/ajra.2011.25.3591.

PMID:
21679527
6.

Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.

Lee RU, White AA, Ding D, Dursun AB, Woessner KM, Simon RA, Stevenson DD.

Ann Allergy Asthma Immunol. 2010 Aug;105(2):130-5. doi: 10.1016/j.anai.2010.05.020. Epub 2010 Jul 1.

PMID:
20674823
7.

Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma.

Ogata N, Darby Y, Scadding G.

J Laryngol Otol. 2007 Dec;121(12):1156-60. Epub 2007 Aug 15.

PMID:
17697437
8.

Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease.

White A, Bigby T, Stevenson D.

Ann Allergy Asthma Immunol. 2006 Aug;97(2):190-5.

PMID:
16937750
9.

Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs.

Campo P, Ayuso P, Salas M, Plaza MC, Cornejo-García JA, Doña I, Torres MJ, Blanca-López N, Canto G, Guéant JL, Sanak M, Blanca M.

Allergy. 2013 Aug;68(8):1001-7. doi: 10.1111/all.12187. Epub 2013 Jul 29.

10.

Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma.

Chang HS, Park JS, Jang AS, Park SW, Uh ST, Kim YH, Park CS.

Allergy Asthma Immunol Res. 2011 Oct;3(4):256-64. doi: 10.4168/aair.2011.3.4.256. Epub 2011 Jul 1.

11.

Aspirin-exacerbated respiratory disease and current treatment modalities.

Sakalar EG, Muluk NB, Kar M, Cingi C.

Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1291-1300. doi: 10.1007/s00405-016-4273-1. Epub 2016 Aug 18. Review.

PMID:
27538737
12.

The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease.

Tajudeen BA, Schwartz JS, Bosso JV.

Curr Opin Otolaryngol Head Neck Surg. 2017 Feb;25(1):30-34. doi: 10.1097/MOO.0000000000000331.

PMID:
27849653
13.
14.

Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.

Cho KS, Soudry E, Psaltis AJ, Nadeau KC, McGhee SA, Nayak JV, Hwang PH.

Otolaryngol Head Neck Surg. 2014 Oct;151(4):575-81. doi: 10.1177/0194599814545750. Epub 2014 Aug 12.

PMID:
25118195
15.

Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Berges-Gimeno MP, Simon RA, Stevenson DD.

J Allergy Clin Immunol. 2003 Jan;111(1):180-6.

PMID:
12532116
16.

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.

Rajan JP, Wineinger NE, Stevenson DD, White AA.

J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1. doi: 10.1016/j.jaci.2014.08.020. Epub 2014 Oct 3.

PMID:
25282015
17.

Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.

Pezato R, Świerczyńska-Krępa M, Niżankowska-Mogilnicka E, Holtappels G, De Ruyck N, Sanak M, Derycke L, Van Crombruggen K, Bachert C, Pérez-Novo CA.

Cytokine. 2016 Jan;77:157-67. doi: 10.1016/j.cyto.2015.10.011. Epub 2015 Nov 23.

PMID:
26615369
18.

Nasal ketorolac challenge using an acoustic rhinomether in patients with aspirin-exacerbated respiratory disease.

Quiralte-Castillo J, Del Robledo Ávila-Castellano M, Cimbollek S, Benaixa P, Leguisamo S, Baynova K, Labella M, Quiralte J.

J Investig Allergol Clin Immunol. 2016 Oct 19:0. doi: 10.18176/jiaci.0118. [Epub ahead of print]

19.

Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.

Jerschow E, Edin ML, Pelletier T, Abuzeid WM, Akbar NA, Gibber M, Fried M, Lih FB, Gruzdev A, Bradbury JA, Han W, Hudes G, Keskin T, Schuster VL, Spivack S, Zeldin DC, Rosenstreich D.

J Allergy Clin Immunol Pract. 2016 Dec 29. pii: S2213-2198(16)30579-7. doi: 10.1016/j.jaip.2016.11.021. [Epub ahead of print]

PMID:
28159558
20.

The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.

Berges-Gimeno MP, Simon RA, Stevenson DD.

Ann Allergy Asthma Immunol. 2002 Nov;89(5):474-8.

PMID:
12452205

Supplemental Content

Support Center